ANAB on Nasdaq
ANAPTYSBIO, INC
$47.42 up 0.75 (1.61%)Price as of Oct 15, 2026 at 14:59 UTC
Last updated Oct 16, 2026.
Overview
Compare with Akebia Therapeutics, Inc., Puma Biotechnology or Keros Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
20.4%Operating margin4
-5.6%Net margin5
157.0%Revenue growth, 20254
-35.6%Return on equity4
$19.6MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢$234.4M
- Income tax0¢$164.0K
Out of $234.6M in revenue.45 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending0¢$87.0K
- Share buybacks100¢$68.6M
Out of $19.7M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.4
Financial statements
Every line of the income statement in the latest annual report, as filed.13
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $234.6M | $91.3M |
| Research and development | -$3.6M | $11.5M |
| General and administrative | $11.3M | $13.6M |
| Total operating expenses | $7.7M | $25.1M |
| (Loss) income from operations | $226.9M | $66.2M |
| Interest income | $9.8M | $15.1M |
| Sublease income | $0 | $0 |
| Non-cash interest expense for the sale of future royalties | -$79.9M | -$50.1M |
| Other (expense) income, net | $5.5M | $0 |
| Total other income (expense), net | -$64.6M | -$35.0M |
| (Loss) income before income taxes | $162.3M | $31.1M |
| Benefit (provision) for income taxes | -$772.0K | -$158.0K |
| Income from continuing operations | $161.5M | $31.0M |
| Loss from discontinued operations, net of tax | -$174.7M | -$176.2M |
| Net income (loss) | -$13.2M | -$145.2M |
| Unrealized (loss) gain on available for sale securities | -$329.0K | $1.1M |
| Comprehensive gain (loss) | -$13.6M | -$144.1M |
| Income from continuing operations - basic | $6 | $1 |
| Loss from discontinued operations - basic | -$6 | -$6 |
| Net income (loss) per common share - basic | -$0.46 | -$5.12 |
| Income from continuing operations - diluted | $5 | $1 |
| Loss from discontinued operations - diluted | -$6 | -$6 |
| Net income (loss) per common share - diluted | -$0.44 | -$4.92 |
| Basic (in shares) | 28.8M shares | 28.4M shares |
| Diluted (in shares) | 30.2M shares | 29.5M shares |
Every line of the balance sheet in the latest annual report, as filed.13
| Period ending | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $133.8M | $138.2M | $23.1M |
| Receivables from collaborative partners | $25.6M | $33.9M | $40.8M |
| Short-term investments | $30.3M | $73.4M | $262.3M |
| Prepaid expenses and other current assets | $8.7M | $0 | $1.2M |
| Current assets of discontinued operations | $0 | $104.8M | $104.6M |
| Total current assets | $198.4M | $350.2M | $431.9M |
| Property and equipment, net | $102.0K | $111.0K | $131.0K |
| Deferred tax asset | $106.6M | $0 | $0 |
| Operating lease right-of-use assets | $11.6M | $12.5M | $14.4M |
| Long-term investments | $0 | $0 | $35.5M |
| Other long-term assets | $256.0K | $256.0K | $256.0K |
| Non-current assets of discontinued operations | $0 | $1.3M | $1.7M |
| Total assets | $317.0M | $364.4M | $483.8M |
| Accounts payable | $4.4M | $3.9M | $4.0M |
| Accrued expenses | $28.8M | $32.7M | $39.5M |
| Current portion of operating lease liability | $2.2M | $2.1M | $1.9M |
| Total current liabilities | $35.4M | $38.6M | $45.4M |
| Liability related to sale of future royalties | $256.5M | $276.5M | $353.4M |
| Long-term taxes payable | $3.6M | $0 | $0 |
| Operating lease liability, net of current portion | $10.9M | $12.0M | $14.1M |
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June 30, 2026, December 31, 2025 and December 31, 2024, respectively | $0 | $0 | $0 |
| Common stock, $0.001 par value, 500,000 shares authorized, 29,728 shares, 28,019 shares and 30,473 shares issued and outstanding at June 30, 2026, December 31, 2025, and December 31, 2024, respectively | $30.0K | $28.0K | $30.0K |
| Additional paid in capital | $652.3M | $809.8M | $829.9M |
| Accumulated other comprehensive (loss) gain | -$151.0K | -$24.0K | $305.0K |
| Accumulated deficit | -$641.6M | -$772.6M | -$759.3M |
| Total stockholders' equity | $10.6M | $37.2M | $70.9M |
| Total liabilities and stockholders' equity | $317.0M | $364.4M | $483.8M |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | 10.0M shares |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | 0 shares |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | 0 shares |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | 500.0M shares |
| Common stock, shares issued (in shares) | 29.7M shares | 28.0M shares | 30.5M shares |
| Common stock, shares outstanding (in shares) | 29.7M shares | 28.0M shares | 30.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.13
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | -$13.2M | -$145.2M |
| Less: Loss from discontinued operations, net of tax | $174.7M | $176.2M |
| Net income from continuing operations | $161.5M | $31.0M |
| Depreciation and amortization | $20.0K | $20.0K |
| Stock-based compensation | $3.8M | $7.2M |
| Accretion/amortization of investments, net | -$4.7M | -$10.3M |
| Amortization of right-of-use assets operating | $1.9M | $1.8M |
| Non-cash interest expense for the sale of future royalties | $79.9M | $50.1M |
| Deferred tax benefit | $0 | $0 |
| Receivables from collaborative partners | $6.9M | -$33.9M |
| Prepaid expenses and other assets | $1.8M | $112.0K |
| Accounts payable and other liabilities | -$87.3M | -$33.8M |
| Income tax receivable | $0 | $0 |
| Operating lease liabilities | -$1.9M | -$1.8M |
| Net cash provided by operating activities of continuing operations | $161.8M | $10.4M |
| Net cash used in operating activities of discontinued operations | -$142.1M | -$145.7M |
| Net cash (used in) provided by operating activities | $19.7M | -$135.3M |
| Purchase of investments | -$196.4M | -$380.4M |
| Sales and maturities of investments | $424.5M | $412.1M |
| Net cash provided by investing activities of continuing operations | $228.1M | $31.7M |
| Net cash used in investing activities of discontinued operations | -$87.0K | -$358.0K |
| Net cash provided by investing activities | $228.0M | $31.4M |
| Proceeds from public offerings, net of underwriters' fees | $0 | $94.4M |
| Proceeds from issuance of common stock | $14.3M | $6.5M |
| Proceeds from the sale of future royalties | $0 | $50.0M |
| Principal repayment of liability for sale of future royalties | -$76.8M | -$15.2M |
| Payments for repurchase of common stock | -$68.6M | -$456.0K |
| Payment for net share settlement of equity awards | -$1.5M | -$7.5M |
| Payments for offering costs, net | $0 | -$492.0K |
| Payments for issuance costs related to the sale of future royalties | $0 | -$103.0K |
| Net cash provided by (used in) financing activities of continuing operations | -$132.6M | $127.1M |
| Net cash used in financing activities of discontinued operations | $0 | $0 |
| Net cash (used in) provided by financing activities | -$132.6M | $127.1M |
| Net (decrease) increase in cash and cash equivalents | $115.1M | $23.1M |
| Interest portion of repayment for sale of future royalties | $80.0M | $42.1M |
| Income taxes paid | $78.0K | $0 |
| Amounts accrued for property and equipment | $0 | $7.0K |
| Amounts accrued for repurchase of common stock | $382.0K | $0 |
| Receivable related to issuance of common stock, upon exercise of stock options | $29.0K | $0 |
Former names
Recent filings
- Oct 2, 20264
- Oct 1, 2026144
- Sep 21, 20268-K
- Sep 21, 202610-KT
- Sep 17, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 11, 20268-K
- Aug 7, 20264
- Aug 7, 20264
- Jul 30, 20268-K
- Jul 13, 2026144
- Jun 30, 2026144
- Jun 29, 2026DEF 14A
- Jun 29, 2026DEFA14A
- Jun 29, 2026ARS
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARANAPTYSBIO, INC filings on SEC EDGAR
- 2Yahoo FinanceANAB quote
- 3SEC EDGARANAPTYSBIO, INC filings on SEC EDGAR
- 4SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2025
- 5SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2025
- 6SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2019
- 7SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2020
- 8SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2021
- 9SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2022
- 10SEC EDGARANAPTYSBIO, INC 10-Q for fiscal 2025
- 11SEC EDGARANAPTYSBIO, INC 10-Q for fiscal 2025
- 12SEC EDGARANAPTYSBIO, INC 10-Q for fiscal 2026
- 13
- 14SEC EDGARANAPTYSBIO, INC 10-K for fiscal 2019